论文部分内容阅读
目的探讨厄贝沙坦消退粥样斑块的机制。方法将40只实验兔随机分为正常对照组10只和实验组30只,正常对照组喂普通饲料,而实验组喂高脂饲料12周后,改喂普通饲料并随机分为自然消退组、辛伐他汀组和厄贝沙坦组各10只,分别给予辛伐他汀和厄贝沙坦治疗12周。测定血清血脂浓度及斑块内膜和中膜厚度,免疫组化法检测斑块内血管细胞粘附分子-1(VCAM-1)、成纤维细胞生长因子2(FGF2)和Bcl-2蛋白的表达。结果与自然消退组相比,厄贝沙坦组的血脂无统计学差异(P>0.05),其斑块内膜厚度、内膜/中膜及VCAM-1、FGF2的表达均降低,Bcl-2的表达增加(P均<0.05)。结论厄贝沙坦可能通过影响VCAM-1、FGF2和Bcl-2的表达而消退斑块。
Objective To investigate the mechanism of irbesartan regressing atherosclerotic plaques. Methods Forty experimental rabbits were randomly divided into normal control group (n = 10) and experimental group (n = 30). The normal control group was fed normal diet, while the experimental group was fed with high-fat diet for 12 weeks, then fed normal diet and randomly divided into spontaneous regression group, Simvastatin group and irbesartan group each 10, were given simvastatin and irbesartan for 12 weeks. Serum lipids and plaque intima and media thickness were measured. The expression of VCAM-1, FGF2 and Bcl-2 protein in plaque was detected by immunohistochemistry expression. Results There was no significant difference in serum lipids in irbesartan group compared with spontaneous regression group (P> 0.05). The plaque intima-media thickness, intima / media, VCAM-1 and FGF2 expression were decreased, but Bcl- 2 expression increased (P <0.05). Conclusion Irbesartan may attenuate the plaque by affecting the expression of VCAM-1, FGF2 and Bcl-2.